236 related articles for article (PubMed ID: 33334316)
21. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2.
Schuman JS
Ophthalmology; 2000 Jun; 107(6):1171-7. PubMed ID: 10857839
[TBL] [Abstract][Full Text] [Related]
22. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group.
Schuman JS; Horwitz B; Choplin NT; David R; Albracht D; Chen K
Arch Ophthalmol; 1997 Jul; 115(7):847-52. PubMed ID: 9230823
[TBL] [Abstract][Full Text] [Related]
23. A review of neuropsychiatric adverse events from topical ophthalmic brimonidine.
Cimolai N
Hum Exp Toxicol; 2020 Oct; 39(10):1279-1290. PubMed ID: 32347114
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.
García-López A; Paczka JA; Jiménez-Román J; Hartleben C
BMC Ophthalmol; 2014 Dec; 14():161. PubMed ID: 25527295
[TBL] [Abstract][Full Text] [Related]
25. Bilateral granulomatous uveitis in an elderly female.
Kattige J; Konana VK; Babu K
Indian J Ophthalmol; 2019 Sep; 67(9):1391. PubMed ID: 31436179
[No Abstract] [Full Text] [Related]
26. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension.
Stewart WC; Sharpe ED; Day DG; Kolker AE; Konstas AG; Lee WH; Rieser JC; Chopra H; Holmes KT
J Ocul Pharmacol Ther; 2000 Jun; 16(3):251-9. PubMed ID: 10872922
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic success of latanoprost 0.005% compared to brimonidine 0.2% in patients with open-angle glaucoma or ocular hypertension.
Stewart WC; Day DG; Stewart JA; Holmes KT; Leech JN; Rowan CT; Schwartz GF
J Ocul Pharmacol Ther; 2000 Dec; 16(6):557-64. PubMed ID: 11132902
[TBL] [Abstract][Full Text] [Related]
28. Brimonidine purite 0.15% versus dorzolamide 2% each given twice daily to reduce intraocular pressure in subjects with open angle glaucoma or ocular hypertension.
Sharpe ED; Day DG; Beischel CJ; Rhodes JS; Stewart JA; Stewart WC
Br J Ophthalmol; 2004 Jul; 88(7):953-6. PubMed ID: 15205246
[TBL] [Abstract][Full Text] [Related]
29. Topical brimonidine 0.2%/timolol 0.5% ophthalmic solution: in glaucoma and ocular hypertension.
Frampton JE
Drugs Aging; 2006; 23(9):753-61. PubMed ID: 17020399
[TBL] [Abstract][Full Text] [Related]
30. Latanoprost and brimonidine: therapeutic and physiologic assessment before and after oral nonsteroidal anti-inflammatory therapy.
Sponsel WE; Paris G; Trigo Y; Pena M; Weber A; Sanford K; McKinnon S
Am J Ophthalmol; 2002 Jan; 133(1):11-8. PubMed ID: 11755835
[TBL] [Abstract][Full Text] [Related]
31. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension.
Goñi FJ;
Eur J Ophthalmol; 2005; 15(5):581-90. PubMed ID: 16167288
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of combined administration of 0.2% brimonidine and 0.5% betaxolol in treatment of primary open angle glaucoma and ocular hypertension.
Chi W; Li A; Wang S; Zhu X
Eye Sci; 2013 Dec; 28(4):190-4. PubMed ID: 24961091
[TBL] [Abstract][Full Text] [Related]
33. [Efficiency of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers].
Carrasco Font C; Arias Puente A; García Sáenz MC; Villarejo Díaz-Maroto I
Arch Soc Esp Oftalmol; 2004 Apr; 79(4):163-8. PubMed ID: 15124072
[TBL] [Abstract][Full Text] [Related]
34. [Brimonidine and acute anterior granulomatous uveitis: A case report and literature review].
Comet A; Donnadieu B; Courjaret JC; Gascon P; Denis D; Matonti F
J Fr Ophtalmol; 2017 Apr; 40(4):e127-e129. PubMed ID: 28336279
[No Abstract] [Full Text] [Related]
35. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension.
Schuman JS
Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S27-37. PubMed ID: 8970247
[TBL] [Abstract][Full Text] [Related]
36. Brimonidine 0.2% versus apraclonidine 0.5% for prevention of intraocular pressure elevations after anterior segment laser surgery.
Chen TC; Ang RT; Grosskreutz CL; Pasquale LR; Fan JT
Ophthalmology; 2001 Jun; 108(6):1033-8. PubMed ID: 11382625
[TBL] [Abstract][Full Text] [Related]
37. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial.
Sherwood MB; Craven ER; Chou C; DuBiner HB; Batoosingh AL; Schiffman RM; Whitcup SM
Arch Ophthalmol; 2006 Sep; 124(9):1230-8. PubMed ID: 16966616
[TBL] [Abstract][Full Text] [Related]
38. Intraocular pressure-lowering effects of latanoprost and brimonidine therapy in patients with open-angle glaucoma or ocular hypertension: a randomized observer-masked multicenter study.
Kampik A; Arias-Puente A; O'Brart DP; Vuori ML;
J Glaucoma; 2002 Apr; 11(2):90-6. PubMed ID: 11912355
[TBL] [Abstract][Full Text] [Related]
39. A comparison of the short-term hypotensive effects and side effects of unilateral brimonidine and apraclonidine in patients with elevated intraocular pressure.
Yüksel N; Karabaş L; Altintaş O; Yildirim Y; Cağlar Y
Ophthalmologica; 2002; 216(1):45-9. PubMed ID: 11901288
[TBL] [Abstract][Full Text] [Related]
40. [Phase III clinical trial of brimonidine in patients with primary open-angle glaucoma and ocular hypertension--comparison of the effects of brimonidine monotherapy versus timolol monotherapy, or combination brimonidine/prostaglandins therapy versus combination placebo/prostaglandins therapy].
Araie M; Yamazaki Y; Sugiyama K; Kuwayama Y; Tanihara H
Nippon Ganka Gakkai Zasshi; 2012 Oct; 116(10):955-66. PubMed ID: 23285843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
